NCT04590378

Brief Summary

The charts of patients who developed pulmonary embolism in the course of COVID-19 will be evaluated, retrospectively. Clinical features and laboratory data will be analyzed.

Trial Health

43
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
600

participants targeted

Target at P75+ for all trials

Timeline
Completed

Started Mar 2020

Geographic Reach
1 country

1 active site

Status
unknown

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

March 1, 2020

Completed
8 months until next milestone

First Submitted

Initial submission to the registry

October 14, 2020

Completed
5 days until next milestone

First Posted

Study publicly available on registry

October 19, 2020

Completed
8 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

June 1, 2021

Completed
6 months until next milestone

Study Completion

Last participant's last visit for all outcomes

December 1, 2021

Completed
Last Updated

May 4, 2021

Status Verified

May 1, 2021

Enrollment Period

1.3 years

First QC Date

October 14, 2020

Last Update Submit

May 1, 2021

Conditions

Covid-19Pulmonary Embolism

Outcome Measures

Primary Outcomes (1)

  • pulmonary embolism

    development of pulmonary embolism

    1 year

Secondary Outcomes (2)

  • Intensive care unit

    1 year

  • mortality

    1 year

Study Arms (2)

Covid-19 Patients with Pulmonary embolism

Clinically demonstared cases infected with COVID-19 who developed pulmonary embolism.

Other: intensive care unit admission ratio

Covid-19 Patients without Pulmonary embolism

Clinically demonstared cases infected with COVID-19 who did not develop pulmonary embolism.

Other: intensive care unit admission ratio

Interventions

intensive care unit admission ratioOTHER

intensive care unit admission ratio

Covid-19 Patients with Pulmonary embolismCovid-19 Patients without Pulmonary embolism

Eligibility Criteria

Age18 Years - 80 Years
Sexall
Age GroupsAdult (18-64), Older Adult (65+)
Sampling MethodProbability Sample
Study Population

All COVID-19 patients with positive RT-PCR tests will be analyzed retrospectively. Patients with and without pulmonary embolism will be compared in terms of age, gender, side disease, hospitalization in intensive care, mortality rates etc.

You may qualify if:

  • \- All patients with positive RT-PCR for COVID-19

You may not qualify if:

  • \- All patients with negative RT-PCR for COVID-19

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Uşak University

Uşak, 64200, Turkey (Türkiye)

RECRUITING

MeSH Terms

Conditions

COVID-19Pulmonary Embolism

Condition Hierarchy (Ancestors)

Pneumonia, ViralPneumoniaRespiratory Tract InfectionsInfectionsVirus DiseasesCoronavirus InfectionsCoronaviridae InfectionsNidovirales InfectionsRNA Virus InfectionsLung DiseasesRespiratory Tract DiseasesEmbolismEmbolism and ThrombosisVascular DiseasesCardiovascular Diseases

Study Officials

  • Cevdet Duran, M.D.

    Uşak University Medical School

    PRINCIPAL INVESTIGATOR

Central Study Contacts

Cevdet Duran, M.D.

CONTACT

+905334298585drcduran@gmail.com

Study Design

Study Type
observational
Observational Model
COHORT
Time Perspective
RETROSPECTIVE
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

October 14, 2020

First Posted

October 19, 2020

Study Start

March 1, 2020

Primary Completion

June 1, 2021

Study Completion

December 1, 2021

Last Updated

May 4, 2021

Record last verified: 2021-05

Data Sharing

IPD Sharing
Will not share

Locations

TU(1)